Gary Goldenberg is Chief Medical Officer at Verrica Pharmaceuticals Inc. (VRCA). They have made 5 open-market trades across 1 company since 2022, most recently 2024-08-27.
CIK 0001741938
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $50K since 2022, against 4 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| VRCA | 97,862 | $332K |
Shares reported on the most recent Form 4, priced at the 2024-08-28 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| VRCA | SELL | 2024-08-26 | 2024-08-28 | $2.61 | $35K | -16.3% | -27.5% | -52.4% |
| VRCA | SELL | 2024-07-22 | 2024-07-23 | $7.06 | $261K | -20.5% | -61.8% | -78.5% |
| VRCA | SELL | 2023-11-14 | 2023-11-16 | $2.94 | $26K | +12.7% | +60.2% | +52.2% |
| VRCA | SELL | 2023-07-24 | 2023-07-25 | $4.83 | $277K | -2.4% | -19.0% | -34.2% |
| VRCA | BUY | 2022-07-05 | 2022-07-05 | $2.10 | $50K | +22.1% | +20.5% | +13.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.